6533b7d7fe1ef96bd1269034
RESEARCH PRODUCT
New landscapes and horizons in hepatocellular carcinoma therapy
Alessandro GulinoLinda S. SteelmanMaria Rita EmmaLydia GiannitrapaniLydia GiannitrapaniGiuseppa AugelloAntonella CusimanoJames A. MccubreyMelchiorre CervelloMaurizio SoresiBeatrice BelmonteGiuseppe MontaltoGiuseppe MontaltoShaw M. AkulaStephen L. Abramssubject
OncologySorafenibmedicine.medical_specialtySettore MED/09 - Medicina InternaCarcinoma Hepatocellularmedicine.medical_treatmentAntineoplastic AgentsReviewTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicinemedicineBiomarkers TumorcancerHumansHCC030304 developmental biology0303 health sciencesbusiness.industryagingLiver NeoplasmsCancerCell BiologyImmunotherapyGenetic Therapymedicine.diseaseOmicstargeted therapyImmune checkpointdigestive system diseases3. Good healthGene Expression Regulation Neoplastic030220 oncology & carcinogenesisHepatocellular carcinomaimmunotherapybusinessmedicine.drugPersonal genomicsdescription
Hepatocellular carcinoma (HCC), is the sixth most frequent form of cancer and leads to the fourth highest number of deaths each year. HCC results from a combination of environmental factors and aging as there are driver mutations at oncogenes which occur during aging. Most of HCCs are diagnosed at advanced stage preventing curative therapies. Treatment in advanced stage is a challenging and pressing problem, and novel and well-tolerated therapies are urgently needed. We will discuss further advances beyond sorafenib that target additional signaling pathways and immune checkpoint proteins. The scenario of possible systemic therapies for patients with advanced HCC has changed dramatically in recent years. Personalized genomics and various other omics approaches may identify actionable biochemical targets, which are activated in individual patients, which may enhance therapeutic outcomes. Further studies are needed to identify predictive biomarkers and aberrantly activated signaling pathways capable of guiding the clinician in choosing the most appropriate therapy for the individual patient.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-02-01 | Aging (Albany NY) |